ATE175120T1 - Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1 - Google Patents

Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1

Info

Publication number
ATE175120T1
ATE175120T1 AT92914115T AT92914115T ATE175120T1 AT E175120 T1 ATE175120 T1 AT E175120T1 AT 92914115 T AT92914115 T AT 92914115T AT 92914115 T AT92914115 T AT 92914115T AT E175120 T1 ATE175120 T1 AT E175120T1
Authority
AT
Austria
Prior art keywords
attenuated
backmutated
vaccine against
virus vaccine
virus
Prior art date
Application number
AT92914115T
Other languages
English (en)
Inventor
Richard L Witter
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Application granted granted Critical
Publication of ATE175120T1 publication Critical patent/ATE175120T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92914115T 1991-06-28 1992-06-26 Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1 ATE175120T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/723,037 US5849299A (en) 1991-06-28 1991-06-28 Attenuated revertant serotype 1 marek's disease vaccine

Publications (1)

Publication Number Publication Date
ATE175120T1 true ATE175120T1 (de) 1999-01-15

Family

ID=24904551

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92914115T ATE175120T1 (de) 1991-06-28 1992-06-26 Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1

Country Status (13)

Country Link
US (1) US5849299A (de)
EP (1) EP0591384B1 (de)
JP (1) JPH06508634A (de)
KR (1) KR940701272A (de)
AT (1) ATE175120T1 (de)
AU (1) AU669849B2 (de)
CA (1) CA2112225C (de)
DE (1) DE69228063D1 (de)
IL (1) IL102297A (de)
MX (1) MX9203436A (de)
NZ (1) NZ243251A (de)
WO (1) WO1993000112A1 (de)
ZA (1) ZA924654B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114501A (en) * 1994-07-14 1999-08-17 Akzo Nobel Nv Marek's disease virus vaccine
EP0703294A1 (de) * 1994-07-14 1996-03-27 Akzo Nobel N.V. Virusimpfstoff gegen Mareksche Krankheit
US6475770B1 (en) 1997-06-10 2002-11-05 Pfizer, Inc. Processes for preparation of Marek's Disease using continuous mammalian cell lines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8401120A (nl) * 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US4895717A (en) * 1987-07-10 1990-01-23 The United States Of America As Represented By The Secretary Of Agriculture Revertant serotype 1 Marek's disease vaccine
FR2666589B1 (fr) * 1990-09-07 1994-08-05 Rhone Merieux Nouveaux virus herpes recombinants, vaccin a base de ces recombinants, leur procede de preparation, genes, vecteurs et plasmides utilises dans ce procede.

Also Published As

Publication number Publication date
NZ243251A (en) 1993-11-25
AU669849B2 (en) 1996-06-27
IL102297A (en) 1996-09-12
CA2112225A1 (en) 1993-01-07
MX9203436A (es) 1994-06-30
EP0591384B1 (de) 1998-12-30
AU2240692A (en) 1993-01-25
IL102297A0 (en) 1993-01-14
DE69228063D1 (de) 1999-02-11
EP0591384A4 (de) 1995-01-18
CA2112225C (en) 2003-08-19
WO1993000112A1 (en) 1993-01-07
US5849299A (en) 1998-12-15
KR940701272A (ko) 1994-05-28
ZA924654B (en) 1993-03-31
JPH06508634A (ja) 1994-09-29
EP0591384A1 (de) 1994-04-13

Similar Documents

Publication Publication Date Title
DE69527202D1 (de) Proteinartige adjuvantien
Wiktor Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin
EP0232798A3 (de) Pseudorabies-Virus-Mutanten, diese enthaltende Vakzine, Verfahren zu deren Herstellung sowie Methoden für deren Anwendung
LU91596I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique,d'antoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, de virus poliomyélitique inactivé type 1, type 2 et type 3 et de polyoside capsulaire d'haemophilus influenzae type b (Infanrix - IPV/Hib)
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
FI842215A0 (fi) Foerfarande foer framstaellning av levande effektiveringsvaccin och pao detta saett erhaollna vaccin.
ATE274355T1 (de) Impfstoffe-zusammensetzungen die inaktivierte immunogene und lebende hühner-anäemie-virus enthalten
TW340873B (en) Chicken anaemia agent vaccine
ATE175120T1 (de) Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
ATE285791T1 (de) Impfstoff, der acemannan als adjuvans enthält
HUP0104125A2 (hu) Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal
MY141983A (en) Hepatitis b virus surface antigen as a mucosal immunoenhancer, resulting formulations
ZA200101583B (en) Chicken anaemia viruses of low pathogenicity.
ATE62134T1 (de) Biologische zubereitungen.
DE60120840D1 (de) Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit
ATE177010T1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
Oya Present status and future prospects of vaccine development.
IE45441L (en) Influenza virus vaccine.
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties